# Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

> clinical trial · VERIFIED · 2026-08-04

Status: RECRUITING · Sponsor: Beijing Biotech · Condition: Small Cell Lung Cancer (SCLC)

- Company: Beijing Biotech
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07744256

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.